Cilostazol combined with P2Y₁₂ receptor inhibitors: A substitute antiplatelet regimen for aspirin-intolerant patients undergoing percutaneous coronary stent implantation.

ABSTRACT:

Background

Cilostazol combined with P2Y₁₂ receptor inhibitor has been used as a substitute regimen for aspirin-intolerant patients undergoing percutaneous coronary stent implantation on a small scale. Its exact impact on platelet functions and clinical benefits of aspirin-intolerant patients is unknown.

Hypothesis

Cilostazol combined with P2Y₁₂ receptor inhibitors could be used as a substitute antiplatelet regimen for aspirin-intolerant patients undergoing percutaneous coronary stent implantation.

Methods

In this multicenter prospective cohort trial, patients undergoing elective percutaneous coronary stent implantation were assigned to the cilostazol group (cilostazol plus P2Y₁₂ receptor inhibitors), based on aspirin intolerance criter

SUBMITTER: Zhao Y 

PROVIDER: S-EPMC8860475 | biostudies-literature | 2022 Feb

REPOSITORIES: biostudies-literature